PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21596884-1	2011	BACKGROUND: We performed this study to determine how dexmedetomidine would affect regional cerebral blood flow (rCBF) and microregional O(2) consumption during nonhemorrhagic normovolemia and during severe hemorrhagic hypotension in rats.	Dexmedetomidine	53-68	CCAAT/enhancer binding protein zeta	Rattus norvegicus	112-116	
21596884-10	2011	In normovolemia, dexmedetomidine significantly decreased rCBF (-58%) in the lateral cortex with a similar percentage decrease (-57%) of calculated O(2) consumption.	Dexmedetomidine	17-32	CCAAT/enhancer binding protein zeta	Rattus norvegicus	57-61	
21596884-13	2011	In contrast, in the lateral cortex of the dexmedetomidine-treated rats, the decrease of rCBF was not significant but there was a significant decrease in regional cerebrovascular resistance.	Dexmedetomidine	42-57	CCAAT/enhancer binding protein zeta	Rattus norvegicus	88-92	
21596884-15	2011	Despite significantly lower rCBF (-34%) in the dexmedetomidine-treated rats, the Svo(2) was similar between the normal saline-treated (42.8% +- 2.5%) and the dexmedetomidine-treated rats (43.2% +- 2.7%).	Dexmedetomidine	47-62	CCAAT/enhancer binding protein zeta	Rattus norvegicus	28-32	
21596884-16	2011	CONCLUSIONS: Our data showed that in normovolemia, dexmedetomidine produced a proportionate decrease of rCBF and O(2) consumption.	Dexmedetomidine	51-66	CCAAT/enhancer binding protein zeta	Rattus norvegicus	104-108	
21596884-18	2011	Dexmedetomidine prevented rCBF and O(2) consumption from decreasing after hemorrhage.	Dexmedetomidine	0-15	CCAAT/enhancer binding protein zeta	Rattus norvegicus	26-30